Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.26 USD

51.26
3,013,431

-1.59 (-3.01%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $51.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View

Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.

    Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2

    Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.

      BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

      BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.

        ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up

        ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.

          Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

          Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.

            Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised

            Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.

              AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact

              AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.

                Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat

                Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.

                  Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat

                  Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.

                    Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance

                    Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.

                      Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View

                      Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.

                        Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View

                        Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.

                          Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

                          Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.

                            Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

                            Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

                              Merck's Biosimilar Insulin Gets Tentative FDA Approval

                              Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

                                Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

                                  Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

                                  Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

                                    Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

                                    Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

                                      Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

                                      Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                                        Perrigo Company Gets FDA Approval for Generic Topical Gel

                                        Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

                                          Sheraz Mian headshot

                                          Early Read on the Q2 Earnings Season

                                          I am reasonably confident that we are on our way for another reassuring earnings read.

                                            AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

                                            AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

                                              Swarup Gupta headshot

                                              Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses

                                              Dovish comments from Yellen helped global stocks post gains.

                                                Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit

                                                Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.

                                                  Pfizer Xeljanz Label Expansion Application Accepted by FDA

                                                  Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.